WS #15043
The biotech sector is experiencing renewed momentum from major international partnerships, particularly involving Chinese firms. AstraZeneca's $2 billion equity investment in Summit Therapeutics to commercialize Akeso's cancer drug, along with a deal from Merck, has lifted shares of Akeso and Summit. This trend underscores global interest in Chinese biotech capabilities despite lingering regulatory uncertainties.
Biotech M&A and Global Deals
The biotech sector is experiencing renewed momentum from major international partnerships, particularly involving Chinese firms. AstraZeneca's $2 billion equity investment in Summit Therapeutics to commercialize Akeso's cancer drug, along with a deal from Merck, has lifted shares of Akeso and Summit. This trend underscores global interest in Chinese biotech capabilities despite lingering regulatory uncertainties.